Nothing Special   »   [go: up one dir, main page]

Faulhammer et al., 2014 - Google Patents

Low-dose capsule filling of inhalation products: Critical material attributes and process parameters

Faulhammer et al., 2014

Document ID
11588061156995507980
Author
Faulhammer E
Fink M
Llusa M
Lawrence S
Biserni S
Calzolari V
Khinast J
Publication year
Publication venue
International journal of pharmaceutics

External Links

Snippet

The aim of the present work was to identify the material attributes and process parameters of a dosator-nozzle capsule filling machine that are critical in low-fill weight capsule filling for inhalation therapies via hard-gelatin capsules. Twelve powders, mostly inhalation carriers …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Similar Documents

Publication Publication Date Title
Faulhammer et al. Low-dose capsule filling of inhalation products: Critical material attributes and process parameters
Guenette et al. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design
Taylor et al. Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development
Shur et al. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations
Cordts et al. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance
Faulhammer et al. The effects of material attributes on capsule fill weight and weight variability in dosator nozzle machines
Faulhammer et al. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance
Kou et al. Physico-chemical aspects of lactose for inhalation
Faulhammer et al. Performance indicators for carrier-based DPIs: Carrier surface properties for capsule filling and API properties for in vitro aerosolisation
Pilcer et al. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations
Pitchayajittipong et al. Characterisation and functionality of inhalation anhydrous lactose
Majerová et al. Effect of colloidal silica on rheological properties of common pharmaceutical excipients
Shur et al. Effect of device design and formulation on the in vitro comparability for multi-unit dose dry powder inhalers
Vanbillemont et al. New advances in the characterization of lyophilised orally disintegrating tablets
Svačinová et al. Comprehensive study of co-processed excipients F-Melts®: Flow, viscoelastic and compacts properties
Zellnitz et al. Spherical agglomerates of lactose as potential carriers for inhalation
Stranzinger et al. The effect of material attributes and process parameters on the powder bed uniformity during a low-dose dosator capsule filling process
Stegemann et al. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance
Benassi et al. Quantifying the loading capacity of a carrier-based DPI formulation and its dependence on the blending process
Blanco et al. Image-based characterization of powder flow to predict the success of pharmaceutical minitablet manufacturing
Haware et al. Vegetable-derived magnesium stearate functionality evaluation by DM3 approach
Rudén et al. On the relationship between blend state and dispersibility of adhesive mixtures containing active pharmaceutical ingredients
Wu et al. Influence of moisture content on die filling of pharmaceutical powders
Virtanen et al. Granule size distribution of tablets
Mao et al. Harnessing ordered mixing to enable direct-compression process for low-dose tablet manufacturing at production scale